This study compares the toxic effects of native cyclosporia A (CyA) with those of targeted CyA that is conjugated with the anti-rat-thymocyte antibody of rabbit origin via the N-(2-hydroxypropyl)methacrylamide (HPMA) carrier bearing digestible, reactive oligopeptide side chains. Ten toxic doses of native CyA (50 mg/kg i.p.) given to young adult rats in the course of 14 d produced a severe renal lesion-diffuse microvacuolization of the proximal tubules in the deep cortex, and hypergranulation of juxtaglomerular regions. Severe atrophy of the thymic medulla was documented by morphometry. In the cortex the epithelial reticular (but not deep interdigitating) cells showed ultrastructural signs of severe degeneration and lysis. The immature CD4+8+ double-positive cortical lymphocytes were preserved whereas the single-positive medullary thymocytes were greatly depleted; there was also a restriction of MHC class II antigen expression in the medulla. The number of medullary B cells was increased. The cytokeratin net was focally shrunken in the cortex and almost negative in the medulla, with loss of Hassall's corpuscles. After ten corresponding doses of antibody-targeted conjugated CyA no damage to the renal tubules and arterioles appeared and the antiGBM or immune-complex deposition was absent. The thymus had a normal medulla with numerous mature thymocytes and the cortical epithelial reticulum remained well preserved. Thus, the main toxic effects of CyA could be eliminated by targeting. The T-cell-targeted drug was tested for preserved immunosuppressive properties and non-toxic character of HPMA copolymer carrier.

Institute of Microbiology Academy of Sciences of the Czech Republic Prague

Zobrazit více v PubMed

Transplant Proc. 1988 Jun;20(3 Suppl 3):759-71 PubMed

Biomaterials. 1989 Jul;10(5):335-42 PubMed

Transplant Proc. 1992 Aug;24(4 Suppl 2):4-7 PubMed

Transplant Proc. 1988 Jun;20(3 Suppl 3):951-8 PubMed

J Immunol. 1984 Sep;133(3):1241-9 PubMed

N Engl J Med. 1984 Sep 13;311(11):699-705 PubMed

Transplantation. 1988 Nov;46(5):694-703 PubMed

Clin Immunol Immunopathol. 1988 Jan;46(1):100-14 PubMed

Clin Immunol Immunopathol. 1993 Mar;66(3):185-92 PubMed

Transplantation. 1988 Feb;45(2):349-53 PubMed

Cell Tissue Res. 1982;224(2):291-301 PubMed

Transplantation. 1981 Oct;32(4):271-7 PubMed

Transplant Proc. 1987 Feb;19(1 Pt 2):1181-3 PubMed

Virchows Arch A Pathol Anat Histol. 1981;392(1):7-20 PubMed

Transplant Proc. 1989 Feb;21(1 Pt 1):810-5 PubMed

Science. 1988 Sep 23;241(4873):1655-8 PubMed

Transplant Proc. 1991 Feb;23(1 Pt 1):41-2 PubMed

Year Immunol. 1988;3:89-118 PubMed

Transplant Proc. 1989 Feb;21(1 Pt 2):1485 PubMed

Nephron. 1986;44(1):26-31 PubMed

Transplant Proc. 1992 Aug;24(4 Suppl 2):67-70 PubMed

J Exp Med. 1984 Apr 1;159(4):1149-68 PubMed

Pathol Res Pract. 1990 Aug;186(4):491-506 PubMed

Eur J Immunol. 1973 Oct;3(10):645-9 PubMed

Virchows Arch A Pathol Anat Histopathol. 1991;418(2):129-41 PubMed

J Pathol. 1982 Oct;138(2):163-78 PubMed

Am J Pathol. 1987 Mar;126(3):487-96 PubMed

Transplant Proc. 1987 Apr;19(2 Suppl 1):1-6 PubMed

Transplant Proc. 1987 Apr;19(2 Suppl 1):17-20 PubMed

Transplant Proc. 1988 Jun;20(3 Suppl 3):540-3 PubMed

Transplant Proc. 1991 Aug;23(4):2115-8 PubMed

Transplant Proc. 1986 Dec;18(6 Suppl 5):41-5 PubMed

J Clin Invest. 1971 Jul;50(7):1525-35 PubMed

Doxorubicin attached to HPMA copolymer via amide bond modifies the glycosylation pattern of EL4 cells

Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice

Morphology and immunohistochemistry of rat aortic grafts

Antibody-targeted polymer-bound drugs